Sara Karlovitch

Eric Pujade-Lauraine, MD, PhD, discussed PARP inhibitors and the benefits of various testing methods for HRD, in an interview with Targeted Oncology ahead of the Society of Gynecologic Oncology Annual Meeting on Women's Cancer.

The Center for Cancer and Blood Disorders, which serves 12,000 patients a year in North Texas, is now offering their patients and caregivers the COVID-19 vaccine.

Despite the coronavirus disease 2019 pandemic, major progress in cancer research has been made in the past year in the areas of molecular profiling, biomarker-driven treatment approaches, targeted therapies brought into earlier stages of disease, treatment combinations with limited toxicities, and treatments that extend survival for hard-to-treat cancers.

In an interview with Ecaterina Ileana Dumbrava, MD, discussed the ongoing study of BDC-1001 alone and in combination with an immune checkpoint inhibitor for the treatment of HER2-positive breast cancer and other solid tumors.

Nemvaleukin alfa, an interleukin-2 variant immunotherapy for the treatment of mucosal melanoma, has been granted orphan drug designation by the FDA,

In an interview with Targeted Oncology, Joyce O’Shaughnessy, MD, chair of Breast Cancer Research and chair of Breast Cancer Prevention Research at Baylor-Sammons Cancer Center of Texas Oncology, discussed the CONTESSA stusy of tesetaxel with a reduced dose of capecitabine versus capecitabine alone in patients with HR-positive, HER2-negative breast cancer.

The FDA granted Breakthrough Device Designation for RaDaR assay, a personalized liquid biopsy assay that tracks a set of up to 48 tumor-specific variants in patients with exceptional sensitivity.

In an interview with Targeted Oncology, Julia K. Rotow, MD, a medical oncologist at the Dana-Farber Cancer institute, discuses the results of the study of gefitinib in combination with osimertinib as frontline treatment of patients with EGFR-mutated NSCLC.

Atezolizumab (is being voluntarily withdrawn from the US market by Roche for its indication as a treatment for patients with prior-platinum treated metastatic urothelial carcinoma.

The novel combined immunotherapy CRX100 has been dosed in the first patient with refractory solid tumors in a phase 1, open-label, dose-escalation study.

The first patient with acute myeloid leukemia in a phase 2 trial of the MultiTAA-specific T cell, MT-401 followed stem-cell transplant has been dosed with the agent, according to a press release by Marker Therapeutics, Inc.

In an interview with Targeted Oncology, Hang Quach, MD, discussed the phase 2 Australasian Leukaemia and Lymphoma Group MM 018/ Asian Myeloma Network 002 study and how it can impact the treatment of R/R/ multiple myeloma in the future.

Treatment with lanreotide autogel in patients with pancreatic neuroendocrine tumors, and midgut neuroendocrine tumors did not cause deterioration in quality-of-life, according to new data from the Phase II CLARINET FORTE study.

Here is a look back at the FDA happenings from the month of February 2021.

The first patient has been dosed in the phase 1/2 clinical trial of an oral CDK9 inhibitor targeting MYC-amplified solid tumors known as KB-0742.

The Centers for Medicare & Medicaid Services have found that there is sufficient evidence for the coverage of blood-based biomarker tests to be granted for patients with colorectal cancer once every 3 years or at a specific individual test interval labeled by the FDA.

Three of the country’s leading health and cancer advocacy groups released recommendations on how to close the gap in racial health care disparities, which include increasing community engagement, improving access to care, addressing bias in care delivery, and providing quality and comprehensive care.

The FDA has expanded the use of PD-L1 IHC 22C3 pharmDx assay to include the diagnosis of patients with non-small cell lung cancer, announced the developer, Agilent Technologies, Inc.

The American Society of Clinical Oncology and the American Cancer Society Cancer Action Network is urging state governments to prioritize patients with cancer in the coronavirus disease vaccine distribution.

The final patient with glioblastoma multiforme has been enrolled in the ongoing phase 2 clinical trial of VAL-083, which is evaluating the efficacy, safety, and pharmacokinetics of the agent in patients who have been pre-treated with temozolomide prior to disease recurrence.

The team of oncologic professionals at New Jersey’s only NCI-Designated Comprehensive Cancer Center, Rutgers Cancer Institute, has been expanded to include a new chief of gynecologic oncology.

As the population ages and the rate of cancer screenings fall due to the coronavirus disease 2019 pandemic, the lack of rural oncologists underscores the need for advanced practitioners.

For World Cancer Day, Jeff Patton, MD, discusses COVID-19’s impact on cancer treatment and testing in an interview with Targeted Oncology.

Her appointment comes during the coronavirus disease 2019 vaccination push.

The Florida Cancer Specialists & Research Institute will be welcoming Susmitha Apuri, MD, into its ranks starting July 1, 2019.

Two community oncology and hematology practices will be joining the American Oncology Network, LLC in June and July: Cancer Blood Specialists of Louisville and Hope Cancer Care of Nevada.